| References |
Isotype Control：APC Mouse IgG1, κ Isotype Ctrl Verified Reactivity：Human Reported Reactivity：Chimpanzee Antibody Type：Monoclonal Host Species：Mouse Formulation：µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). Preparation：The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. Concentration：µg sizes: 0.2 mg/mL。test sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.) Storage & Handling：The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. Application：FC - Quality tested Recommended Usage：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Excitation Laser：Red Laser (633 nm) Application Notes：The RPA-T4 antibody binds to the D1 domain of CD4 (CDR1 and CDR3 epitopes) and can block HIV gp120 binding and inhibit syncytia formation. Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections3,4,5, blocking of T cell activation1,2, and spatial biology (IBEX)10,11. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300569 - 300574). Application References：(PubMed link indicates BioLegend citation) Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. (Activ) Moir S, et al. 1999. J. Virol. 73:7972. (Activ) Deng MC, et al. 1995. Circulation 91:1647. (IHC) Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC) Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC) Lan RY, et al. 2006. Hepatology 43:729. Zenaro E, et al. 2009. J. Leukoc. Biol. 86:1393. (FC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations： Tang-Huau TL, et al. 2018. Nat Commun. 9:2570. PubMed
Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed Wang F, et al. 2018. Oncogenesis. 7:41. PubMed Eri Yamada et al. 2018. Cell host & microbe. 23(1):110-120 . PubMed Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed Tang M, et al. 2019. Biomed Res Int. 2019:1050285. PubMed Park MJ, et al. 2019. J Immunol. 203:127. PubMed Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed Martin GE, et al. 2018. Front Immunol. 1.019444444. PubMed Lundy SK, et al. 2018. Front Med (Lausanne). 0.38125. PubMed
See More
RRID AB_314082 (BioLegend Cat. No. 300514)
AB_2564153 (BioLegend Cat. No. 300552)
AB_2562051 (BioLegend Cat. No. 300537)
|
